Bing Lu

Bing Lu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LZLan Zhang
Lan Zhang
JXJiale Xie
Jiale Xie
WDWenyu Dai
Wenyu Dai
BLBing Lu
Bing Lu
SYSheng Yi
Sheng Yi
Schwann cells are specific peripheral glial cells with remarkable plasticity following peripheral nerve injury. Injury responses stimulate c-Jun activation in Schwann cells, drive epithelial-mesenchymal transition and cellular phenotypic changes, and induce the generation of reprogrammed repair Schwann cells to orchestrate peripheral nerve regeneration process. Schwann cells and/or Schwann cell-derived molecules are commonly used as supporting cells and/or neurotrophic factors to construct Schwann cell-based tissue-engineered nerve grafts for repairing severe peripheral nerve injury with long defects. Transplantation of Schwann cells and/or Schwann cell-derived molecules also serves as a helpful approach for the treatment of other injured tissues, such as the spinal cord, skin, digit tip, and bone. Schwann cells are not only associated with tissue regeneration but also involved in tumorigenesis and tumor progression. Schwann cells are the major cellular component of neurofibromatosis type 1 and the sole cell type in neurofibromatosis type 2 and schwannomatosis. In addition, Schwann cells also function as an important player in the tumor microenvironment and aid in the growth and invasiveness of many other solid cancers. In the present review, we outline the physiological and pathological activities of Schwann cells and discuss the functional roles of Schwann cells in homeostasis, regeneration, and cancer.

15 November 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
QWQianqian Wu
Qianqian Wu
SJSutian Jiang
Sutian Jiang
TCTong Cheng
Tong Cheng
MXManyu Xu
Manyu Xu
BLBing Lu
Bing Lu
Hepatocellular carcinoma (HCC) is the second most lethal malignant tumor because of its significant heterogeneity and complicated molecular pathogenesis. Novel prognostic biomarkers are urgently needed because no effective and reliable prognostic biomarkers currently exist for HCC patients. Increasing evidence has revealed that pyroptosis plays a role in the occurrence and progression of malignant tumors. However, the relationship between pyroptosis-related genes (PRGs) and HCC patient prognosis remains unclear. In this study, 57 PRGs were obtained from previous studies and GeneCards. The gene expression profiles and clinical data of HCC patients were acquired from public data portals. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis was performed to establish a risk model using TCGA data. Additionally, the risk model was further validated in an independent ICGC dataset. Our results showed that 39 PRGs were significantly differentially expressed between tumor and normal liver tissues in the TCGA cohort. Functional analysis confirmed that these PRGs were enriched in pyroptosis-related pathways. According to univariate Cox regression analysis, 14 differentially expressed PRGs were correlated with the prognosis of HCC patients in the TCGA cohort. A risk model integrating two PRGs was constructed to classify the patients into different risk groups. Poor overall survival was observed in the high-risk group of both TCGA (p < 0.001) and ICGC (p < 0.001) patients. Receiver operating characteristic curves demonstrated the accuracy of the model. Furthermore, the risk score was confirmed as an independent prognostic indicator via multivariate Cox regression analysis (TCGA cohort: HR = 3.346, p < 0.001; ICGC cohort: HR = 3.699, p < 0.001). Moreover, the single-sample gene set enrichment analysis revealed different immune statuses between high- and low-risk groups. In conclusion, our new pyroptosis-related risk model has potential application in predicting the prognosis of HCC patients.

18 May 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
KMKadeerjiang Musha
Kadeerjiang Musha
XGXinqi Ge
Xinqi Ge
NANuraliya Ablikim
Nuraliya Ablikim
BLBing Lu
Bing Lu
CCChen chen
Chen chen
JHJianfei Huang
Jianfei Huang
Background. Receptor expressed in lymphoid tissues-like 2 (RELL2), which is a member of RELT family, is closely associated with the plasma membrane and acts as a modulator for RELT signaling. Overexpression of RELL2 induces the activation of MAPK14/p38 cascade and apoptosis. However, whether RELL2 contributes to cancers remains unclear. Here, we examined its role in cancer patient prognosis and various tumors. Methods. We used several bioinformatics methods, specifically gene set enrichment analysis (GSEA), ScanNeo, and ESTIMATE, to analyze the CCLE dataset, GTEx dataset, and TCGA dataset. We investigated the possible association of RELL2 with the microsatellite instability (MSI) of various tumors, tumor mutational burden (TMB), immune checkpoint, immune neoantigens, immune microenvironment, and patient prognosis. Result. RELL2 is highly expressed in cancer compared with normal tissues. RELL2 expression is linked with worse progression-free interval and overall survival in numerous cancers. In most cancers, high RELL2 expression was related to a poor prognosis. RELL2 expression was significantly associated with the tumor microenvironment, MSI, and TMB. RELL2 expression is strongly associated with phenotypes that are of major clinical significance, particularly those associated with immune neoantigens and the expression profiles of immune checkpoint genes in pan-cancer. RELL2 expression strongly linked with the expressions of methyltransferases and DNA repair genes. It also significantly correlated with multiple signaling pathways through gene set enrichment analysis. Conclusion. RELL2 may be a prognostic biomarker in pan-cancer and may have an important function in tumorigenesis and progression.

19 September 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
TCTong Cheng
Tong Cheng
MXManyu Xu
Manyu Xu
HZHui Zhang
Hui Zhang
BLBing Lu
Bing Lu
XZXiaojing Zhang
Xiaojing Zhang
JHJianfei Huang
Jianfei Huang
Background. The tumor immune microenvironment (TME) is associated with cancer progression and immune escape. Although KLHDC8A has been reported in glioma in vitro, the expression and clinical significance of this gene in clinical samples are unknown. Methods. The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases were used to evaluate the mRNA expression level of KLHDC8A and its significance in the glioma TME. Tissue microarray‐based multiple immunohistochemical staining was conducted to determine KLHDC8A protein levels and characterize the immune signature of tumor‐infiltrating immune cells in gliomas. Results. Tumor cells and tumor‐associated macrophages expressed KLHDC8A. The expression of KLHDC8A was higher in glioma tissues than in normal brain tissues and was associated with patient clinical characteristics. Gliomas exhibited a high abundance of macrophages, neutrophils, regulatory T cells, and the immune checkpoint PD‐L1, as well as high KLHDC8A expression. Cox regression analysis showed that KLHDC8A+CD68+ macrophages and KLHDC8A predicted unfavorable survival in patients with glioma. Finally, protein‐protein interaction network analysis showed that the KLHDC8A expression was associated with hypoxia and oxidative stress. Conclusions. KLHDC8A is a potential marker for the clinical diagnosis of glioma. The immune characteristics of macrophages play a crucial role in predicting patients with glioma, providing a new avenue for targeted glioma therapy.

2 May 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
SRShiqi Ren
Shiqi Ren
WWWei Wang
Wei Wang
CZChenlin Zhang
Chenlin Zhang
YSYidan Sun
Yidan Sun
MSMengjing Sun
Mengjing Sun
LYLanlan Yao
Lanlan Yao
A primary factor in tumor morbidity and mortality, lung adenocarcinoma (LUAD) is known to be a major subtype of lung cancer, having the lowest survival rate among all other cancers. Using The Cancer Genome Atlas (TCGA) database the relationship between the immune infiltrate and the NUP62CL was explored and the value of the NUP62CL expression in the prognosis and diagnosis LUAD was examined. Using the logistic regression and the Wilcoxon signed‐rank test the relationship between the NUP62CL and the clinico‐pathological features was analyzed. There was a significant correlation between the clinical stage (p = 0.005), the N (p = 0.004), and the decreased expression of NUP62CL. The prognosis of LUAD with high NUP62CL expression was revealed to be worse than that with low NUP62CL expression (p < 0.001) by the Kaplan‐Meier survival analysis. The potentiality of NUP62CL to be a significant factor of prognosis for LUAD was indicated by the analyses of the multivariate and the univariate Cox regression models. In LUAD, the crucial role of recombination and maintenance of telomere as a significant pathway for NUP62CL was suggested by the Gene Set Enrichment Analysis (GSEA). To analyze the correlation between the genes and the tumor infiltrating immune cells the CIBERSORT was used. Moreover the positive correlation with the NUP62CL expression in LUAD of the infiltration level of the tumor infiltrating B lymphocytes and memory CD4+ T cells was exhibited by CIBERSORT. Therefore, NUP62CL may be a new valuable prognostic indicator for LUAD.

9 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
BLBing Lu
Bing Lu
MXManyu Xu
Manyu Xu
HZHui Zhang
Hui Zhang
XZXiaojin Zhang
Xiaojin Zhang
PSPingping Sun
Pingping Sun
JHJianfei Huang
Jianfei Huang
Glioma, the most prevalent CNS malignancy and generally poor prognosis, is characterized by a highly immunosuppressive tumor microenvironment. Fucose mutarotase (FUOM) is a known rockulose mutase secretion protein involved in pathological immune remodeling. However, the precise role of FUOM involvement in glioma has yet to be elucidated. Herein, we delineated FUOM expression using multiplex-immunohistochemistry on tissue microarrays, and its prognostic predictive value was assessed using the Cox regression method. Then we investigated the altered proliferation, migration, and invasion capabilities of glioma cells upon regulated FUOM expression in vitro. Chemokine antibody microarray, immunoassay, and Co-IP were employed to detect interactions between macrophages and glioma cells. In addition, the in vivo therapeutic effects of FUOM were confirmed using animal subcutaneous glioma models. FUOM was highly expressed in glioma tissues and correlated with aggressive glioma progression and unfavorable patient prognosis. Macrophage infiltration into the glioma TME was observed upon FUOM downregulation, with induced CXC motif chemokine ligand-13 (CXCL13) release in maintaining M2-like phenotype. In addition, conditioned media from FUOM knockdown glioma cell lines induced M2-like macrophage chemotaxis migration. Finally, blocking FUOM expression on glioma models enhanced M2-like macrophage phenotype and increased chemotactic migration both in vivo and in vitro. Collectively, our work reveals that FUOM induces M2-like macrophage polarization and promotes glioma progression by mediating CXCL13 secretion.